On March 25, 2025 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, reported the presentation of new data from the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Aulos Bioscience, MAR 25, 2025, View Source [SID1234651438]). The presentation will focus on promising results for AU-007 in second-line treatment of melanoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AU-007 is a human IgG1 monoclonal antibody designed with the assistance of artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors in patients with unresectable locally advanced or metastatic cancers. The AACR (Free AACR Whitepaper) Annual Meeting is being held April 25-30, 2025, in Chicago, Illinois.
Details of the poster presentation are as follows:
Poster Title: AU-007, a human monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, plus low-dose aldesleukin, in advanced solid tumors: Phase 2 update
Abstract: CT178
Session Title: Phase II Clinical Trials 1
Date and Time: Tuesday, April 29, 2025, 9:00 a.m.-12:00 p.m. CDT
The poster will be presented in Poster Section 49 at McCormick Place. An electronic version will also be available on the AACR (Free AACR Whitepaper) 2025 virtual meeting platform.
About AU-007
AU-007 is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. AU-007 also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.
To learn more about the AU-007 Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).